Corporate Disclosure and Strategic Outlook – X Bioscience Public Company Limited (Trade Name: COOPER COS INC/THE)
On June 30, 2026, X Bioscience Public Company Limited (hereafter “the Company”) submitted a formal clarification to the Stock Exchange of Thailand (SET) concerning a substantial rise in its operating loss for the first quarter of 2026. The disclosure, prepared in accordance with Thai Securities Law and the Company’s internal reporting standards, provides a detailed account of the underlying drivers, impairment accounting, and forthcoming strategic initiatives across its diversified portfolio of food‑service and biotechnology ventures.
1. Financial Performance – Operating Loss Surge
The Company’s operating loss for Q1 2026 increased sharply compared with the corresponding period in 2025. The principal factors identified were:
| Item | Q1 2026 | Q1 2025 | Variance |
|---|---|---|---|
| Administrative expenses | THB 95 million | THB 68 million | +THB 27 million |
| Impairment charges (goodwill, investments) | THB 120 million | THB 32 million | +THB 88 million |
| Other operating items | – | – | – |
| Total operating loss | THB 245 million | THB 100 million | +THB 145 million |
The sharp escalation is largely attributable to higher administrative costs—primarily linked to the expansion of the Company’s central‑kitchen infrastructure—and to impairment charges associated with food‑business investments.
2. Impairment Analysis
2.1 Goodwill and Investment Impairments
The impairment of goodwill and equity investments was recorded for several subsidiaries, notably HOSHI Co., Ltd.. A repurchase agreement had driven the book value of the HOSHI stake below its cost base, triggering an impairment write‑down. The Company applied a discounted‑cash‑flow (DCF) methodology, incorporating:
- Expected future cash flows from the subsidiary
- A discount rate reflecting the subsidiary’s risk profile
- Sensitivities to market share erosion and the cessation of certain product lines
The resulting impairment loss was recorded as THB 120 million in Q1 2026.
2.2 Impairment of Brand and Software Assets
Separate impairment charges were applied to brand and software assets across various subsidiaries. These were driven by:
- Declining brand equity due to competitive pressure in the fast‑food sector
- Obsolescence of proprietary software in the biotechnology division
The total impairment charge for these categories amounted to THB 30 million.
3. Operational Continuity
The resignation of the Chief Operating Officer (COO) of the food division was communicated as non‑material to ongoing operations. Management structures were confirmed to remain intact, with a succession plan already in place to mitigate any transitional risk.
4. Forward‑Looking Business Policy
4.1 Central‑Kitchen Project
The Company is advancing a central‑kitchen initiative designed to underpin the expansion of its Kizuna restaurant brand. Objectives include:
- Consolidation of food preparation to achieve economies of scale
- Standardization of ingredient sourcing and inventory control
- Reduction of per‑unit operating costs by an estimated 8–10 %
Projected capital expenditure for the central kitchen is THB 200 million, with an anticipated breakeven point in the fourth quarter of 2027.
4.2 New Food‑Business Subsidiary – Chokdee Dim Sum
A capital allocation of THB 288 million will be deployed to establish Chokdee Dim Sum, a new food‑business subsidiary slated to launch in Q2 2026. The venture will focus on authentic dim‑sum offerings, targeting urban middle‑income consumers and leveraging the Company’s existing supply-chain efficiencies.
4.3 Construction Projects Portfolio
During Q1 2026, the Company signed contracts for two additional construction projects, raising the total to seven ongoing projects. These projects span:
- Expansion of the Kizuna brand
- Renovation of the French‑style restaurant Le Bouef
- Development of ancillary service facilities (e.g., catering kitchens)
Each project has a defined completion timetable and a staged payment schedule aligned with construction milestones.
5. Advance Payments and Deposits
The Company clarified its policy on advance payments and deposits:
- 10 million THB deposit for a prospective investment in Charoensuk Passion Co., Ltd. – earmarked for a potential joint‑venture in the dessert segment.
- Deposit related to a land purchase that was subsequently cancelled and refunded, illustrating adherence to prudent capital‑allocation practices.
- Renovation deposit for Le Bouef – tied to a lease‑expiration arrangement, with a construction contract scheduled for completion by mid‑July 2026.
All deposits are proportionate to contract value, consistent with industry norms, and governed by clear delivery schedules and payment terms to minimize liquidity risk.
6. Industry Context and Cross‑Sector Implications
X Bioscience operates at the intersection of biotechnology and food‑service industries, sectors that are experiencing divergent yet convergent dynamics:
- Biotechnology: Intensifying R&D expenditures and regulatory hurdles are elevating operating costs, a trend mirrored in the Company’s increased administrative expenses.
- Food‑service: Consumer preferences for experiential dining and digital ordering platforms are reshaping cost structures, necessitating capital investment in centralized kitchens and digital infrastructure.
The Company’s strategic pivot toward centralized operations and brand expansion reflects a broader industry shift toward scale‑based cost efficiencies and diversification of revenue streams. Its impairment accounting signals a cautious approach to asset valuation in an environment of rapid market consolidation and heightened competition.
7. Conclusion
X Bioscience’s disclosure highlights a period of significant financial adjustment driven by higher operating costs and strategic impairments. The Company’s forward‑looking initiatives—central‑kitchen development, new brand launches, and careful management of advance payments—demonstrate an adaptive strategy aimed at sustaining competitive positioning across its dual sectors. Investors and analysts should monitor the Company’s execution on capital allocation, operational efficiency, and market response to these initiatives as key indicators of future profitability.
